New York v. Julius Nasso Concrete Corp. et al., 1999-2 Trade Cas. ¶72,767; 202 F.3d 82; Nos. 98-9218, 98-9226, 98-9262 (2d Cir. 2000)
New York was successful in its appeal to have trial court decision reversed in concrete construction bid-rigging case
New York v. Cedar Park Concrete Corp., NY v. Century-Maxim Construction Corp, 665 F.Supp. 238 (S.D.N.Y. 1987); 684 F.Supp. 1229 (S.D.N.Y. 1988); 741 F.Supp. 494 (S.D.N.Y. 1990).
New York, alleging bid-rigging and market-allocation, sued for treble damages under the Clayton Act and the New York General Business Law (Donnelly Act), for injunctive relief, and civil penalties.
Archer v. Hoffmann-La Roche, Ltd., Roche Vitamins Inc., Aventis Animal Nutrition S.A.; Daiichi Pharmaceutical Co., LTD.; Eisai Co., Ltd; Takeda Chemical Industries, LTD., and Basf Corporation
State intervened in private class action suit following guilty pleas by vitamin manufacturers.
West Virginia ex rel. Tompkins v. Northwestern Disposal Co. et al., No. 90-C-130 (Cir. Ct. Wood Cty. 1990).
Case alleged monopolization by owner of only landfill within geographic area.
West Virginia ex rel. McGraw v. Meadow Gold Dairies, Inc., No. 95-C-65 (Cir. Ct. Greenbrier Cty. 1995)
Meadow Gold Dairies conspired with other fluid milk distributors to rig bids and divide the market for supplying milk to public school districts in Southeastern West Virginia
West Virginia ex rel. McGraw v. Meadow Gold Dairies and Valley Rich Dairy, No. 93-0915-R (W.D. Va. 1995)
Meadow Gold and Valley Rich were accused of bid-rigging, market allocation and price fixing fluid milk sold to public schools in Southeastern West Virginia and Virginia. Valley Rich settled the case and Meadow Gold was dismissed. The case against Meadow Gold was refiled in West Virginia State Court. This action followed a guilty plea by Borden, Inc. to federal antitrust charges on rigging bids for school milk programs.
West Virginia ex rel. McGraw v. Abbott Labs and Geneva Pharmaceuticals, Inc., No. 05-C-180 (Cir. Ct. Wyoming Cty. 2005)
The brand name maker of the prescription drug Hytrin, Abbott, entered into an agreement with Geneva to keep Geneva’s generic version of Hytrin off the market. Geneva was paid a substantial amount of money by Abbott while Abbott continued to collect monopoly profits on its name brand drug. Because of federal laws, Geneva effectively blocked the entry of other generic drug makers from entering the market. The matter settled in conjunction with MDL litigation.
New York v. Willis Group Holdings Ltd., Willis North America Inc., Willis of New York, Inc., Assurance of Discontinuance
State of New York sought damages and conduct relief, alleging that Defendant Willis engaged in fraudulent and anti-competitive practices.
New York v. Marsh & McLennan Companies, Inc., Marsh Inc. and their subsidiaries and affiliates
State of New York sought damages and injunctive relief, alleging that Defendant Marsh unlawfully deceived its clients by steering clients’ insurance business and soliciting fictitious bids.
New York v. Aon Corporation
States sought damages and injunctive relief, alleging that defendants unlawfully deceived clients by steering clients’ insurance business, promising increased retail business to insurers in return for their commitments to use Aon’s reinsurance services, suggesting that an insurer raise its quotes for two of Aon’s clients, entering into undisclosed “producer funding agreements” whereby insurers directly funded the hiring of Aon brokers, entering into secret “pay-to-play” arrangements with insurers whereby Aon obtained undisclosed compensation, agreeing with preferred insurers to “freeze out” a competing insurer, and providing preferred insurers with first looks, last looks, and exclusive looks on preferred business.
